Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.84
HSKA's Cash to Debt is ranked higher than
69% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. HSKA: 2.84 )
HSKA' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 2.84

Equity to Asset 0.54
HSKA's Equity to Asset is ranked higher than
63% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. HSKA: 0.54 )
HSKA' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.78
Current: 0.54

0.02
0.78
Interest Coverage 14.13
HSKA's Interest Coverage is ranked higher than
57% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 566.16 vs. HSKA: 14.13 )
HSKA' s 10-Year Interest Coverage Range
Min: 0.8   Max: 26.2
Current: 14.13

0.8
26.2
F-Score: 5
Z-Score: 1.46
M-Score: -2.27
WACC vs ROIC
7.32%
5.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 4.39
HSKA's Operating margin (%) is ranked higher than
76% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. HSKA: 4.39 )
HSKA' s 10-Year Operating margin (%) Range
Min: -125.26   Max: 6.71
Current: 4.39

-125.26
6.71
Net-margin (%) 3.27
HSKA's Net-margin (%) is ranked higher than
78% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. HSKA: 3.27 )
HSKA' s 10-Year Net-margin (%) Range
Min: -132.76   Max: 42.28
Current: 3.27

-132.76
42.28
ROE (%) 5.87
HSKA's ROE (%) is ranked higher than
79% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. HSKA: 5.87 )
HSKA' s 10-Year ROE (%) Range
Min: -104.28   Max: 140.27
Current: 5.87

-104.28
140.27
ROA (%) 3.10
HSKA's ROA (%) is ranked higher than
80% of the 302 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.41 vs. HSKA: 3.10 )
HSKA' s 10-Year ROA (%) Range
Min: -69.96   Max: 61.02
Current: 3.1

-69.96
61.02
ROC (Joel Greenblatt) (%) 14.99
HSKA's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. HSKA: 14.99 )
HSKA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -176.87   Max: 22.95
Current: 14.99

-176.87
22.95
Revenue Growth (3Y)(%) 2.20
HSKA's Revenue Growth (3Y)(%) is ranked higher than
65% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. HSKA: 2.20 )
HSKA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16.9   Max: 10.4
Current: 2.2

-16.9
10.4
EBITDA Growth (3Y)(%) 1.00
HSKA's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. HSKA: 1.00 )
HSKA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.9   Max: 27.7
Current: 1

-63.9
27.7
EPS Growth (3Y)(%) 0.80
HSKA's EPS Growth (3Y)(%) is ranked higher than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. HSKA: 0.80 )
HSKA' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 7.1
Current: 0.8

0
7.1
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

HSKA Guru Trades in Q2 2014

Jim Simons 65,980 sh (+18.07%)
Mario Gabelli 58,000 sh (-3.23%)
» More
Q3 2014

HSKA Guru Trades in Q3 2014

Jim Simons 106,880 sh (+61.99%)
Mario Gabelli 57,500 sh (-0.86%)
» More
Q4 2014

HSKA Guru Trades in Q4 2014

Jim Simons 130,580 sh (+22.17%)
Mario Gabelli 53,000 sh (-7.83%)
» More
Q1 2015

HSKA Guru Trades in Q1 2015

Jim Simons 168,280 sh (+28.87%)
Mario Gabelli 52,400 sh (-1.13%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 64.70
HSKA's P/E(ttm) is ranked higher than
78% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 64.70 )
HSKA' s 10-Year P/E(ttm) Range
Min: 0.5   Max: 549.09
Current: 64.7

0.5
549.09
Forward P/E 42.92
HSKA's Forward P/E is ranked higher than
81% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 42.92 )
N/A
PE(NRI) 65.20
HSKA's PE(NRI) is ranked higher than
80% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 65.20 )
HSKA' s 10-Year PE(NRI) Range
Min: 0.5   Max: 604
Current: 65.2

0.5
604
P/B 3.59
HSKA's P/B is ranked higher than
72% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. HSKA: 3.59 )
HSKA' s 10-Year P/B Range
Min: 0.22   Max: 75.45
Current: 3.59

0.22
75.45
P/S 2.16
HSKA's P/S is ranked higher than
77% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. HSKA: 2.16 )
HSKA' s 10-Year P/S Range
Min: 0.12   Max: 2.19
Current: 2.16

0.12
2.19
EV-to-EBIT 51.44
HSKA's EV-to-EBIT is ranked higher than
77% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 51.44 )
HSKA' s 10-Year EV-to-EBIT Range
Min: -122.2   Max: 164.2
Current: 51.44

-122.2
164.2
Shiller P/E 142.69
HSKA's Shiller P/E is ranked higher than
82% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 142.69 )
HSKA' s 10-Year Shiller P/E Range
Min: 1.88   Max: 144.86
Current: 142.69

1.88
144.86
Current Ratio 2.08
HSKA's Current Ratio is ranked higher than
64% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. HSKA: 2.08 )
HSKA' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.19
Current: 2.08

1.03
5.19
Quick Ratio 1.20
HSKA's Quick Ratio is ranked higher than
53% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. HSKA: 1.20 )
HSKA' s 10-Year Quick Ratio Range
Min: 0.56   Max: 4.4
Current: 1.2

0.56
4.4
Days Inventory 87.82
HSKA's Days Inventory is ranked higher than
77% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. HSKA: 87.82 )
HSKA' s 10-Year Days Inventory Range
Min: 82.09   Max: 163.18
Current: 87.82

82.09
163.18
Days Sales Outstanding 45.72
HSKA's Days Sales Outstanding is ranked higher than
89% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. HSKA: 45.72 )
HSKA' s 10-Year Days Sales Outstanding Range
Min: 14.6   Max: 77.96
Current: 45.72

14.6
77.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.90
HSKA's Dividend Yield is ranked lower than
67% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. HSKA: 0.90 )
HSKA' s 10-Year Dividend Yield Range
Min: 0.79   Max: 3.73
Current: 0.9

0.79
3.73
Yield on cost (5-Year) 0.90
HSKA's Yield on cost (5-Year) is ranked lower than
69% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. HSKA: 0.90 )
HSKA' s 10-Year Yield on cost (5-Year) Range
Min: 0.79   Max: 3.73
Current: 0.9

0.79
3.73
Share Buyback Rate -6.30
HSKA's Share Buyback Rate is ranked higher than
70% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.20 vs. HSKA: -6.30 )
HSKA' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -29.6
Current: -6.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.88
HSKA's Price/Tangible Book is ranked higher than
74% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.76 vs. HSKA: 5.88 )
HSKA' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 261.43
Current: 5.88

0.3
261.43
Price/DCF (Projected) 3.60
HSKA's Price/DCF (Projected) is ranked higher than
84% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 3.60 )
HSKA' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 20.11
Current: 3.6

0.57
20.11
Price/Median PS Value 3.08
HSKA's Price/Median PS Value is ranked higher than
55% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. HSKA: 3.08 )
HSKA' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 18.7
Current: 3.08

0.23
18.7
Price/Graham Number 4.55
HSKA's Price/Graham Number is ranked higher than
83% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. HSKA: 4.55 )
HSKA' s 10-Year Price/Graham Number Range
Min: 0.19   Max: 26.4
Current: 4.55

0.19
26.4
Earnings Yield (Greenblatt) 1.90
HSKA's Earnings Yield (Greenblatt) is ranked higher than
74% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. HSKA: 1.90 )
HSKA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 20.7
Current: 1.9

0.6
20.7
Forward Rate of Return (Yacktman) -0.91
HSKA's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.27 vs. HSKA: -0.91 )
HSKA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -90.7   Max: 7.5
Current: -0.91

-90.7
7.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 µL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 
Heska Corp. (HSKA) President and COO Michael J Mcginley buys 12,290 Shares Feb 26 2010 

More From Other Websites
HESKA CORP Financials May 22 2015
Heska to Present at Stifel Dental & Veterinary Conference May 20 2015
Heska to Present at Stifel Dental & Veterinary Conference May 20 2015
10-Q for Heska Corp. May 16 2015
HESKA CORP Files SEC form 10-Q, Quarterly Report May 14 2015
HESKA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2015
Heska meets 1Q profit forecasts May 07 2015
Heska meets 1Q profit forecasts May 07 2015
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
Heska Reports 10% Revenue Growth, $0.09 Per Share for the First Quarter of 2015 May 07 2015
Webcast Alert: Heska Announces First Quarter 2015 Earnings Conference Call Webcast May 06 2015
Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast May 04 2015
10-K for Heska Corp. May 01 2015
Heska to Present at the 16th Annual B. Riley & Co. Investor Conference May 01 2015
Heska to Present at the 16th Annual B. Riley & Co. Investor Conference May 01 2015
First Quarter 2015 Earnings Conference Call Apr 30 2015
Webcast Alert: Heska Announces First Quarter 2015 Earnings Conference Call Webcast Apr 30 2015
Annual Stockholder Meeting Conference Call Tuesday, May 5, 2015 Apr 29 2015
Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast Apr 28 2015
Peak Pharma Prepares for Human Marketplace as Veterinary Segment Propels Early Commercial Success Apr 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK